Novo Nordisk A/S
Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The blockbuster diabetes drug Ozempic could be manufactured for less than $5 a month, even as Novo Nordisk charges close to $1,000 per month for the injection in the U.S. before insurance, a […]
Read More
Viking Therapeutics stock jumps more than 15% on promising weight loss pill data
Alexey Krukovsky | Istock | Getty Images Viking Therapeutics shares jumped more than 15% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker’s prospects in […]
Read More
Amgen wants in on the booming weight loss drug market — and it's taking a different approach
The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images Amgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. The biotech company is testing an injectable […]
Read More
Here's how much people are willing to spend on weight loss drugs, according to a new survey
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Demand for weight loss drugs is booming in the U.S. despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. But some patients are willing to pay more out of […]
Read More
Medicare can now cover certain weight loss drugs in a big step for patients
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Medicare can start covering certain weight loss drugs for the first time – as long as they are approved for an added health benefit, the Centers for Medicare and Medicaid Services said Thursday. […]
Read More
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
3D Illustration of a human liver organ. magicmine | iStock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for […]
Read More
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of […]
Read More
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of […]
Read More
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. Rafael Henrique | SOPA Images | Lightrocket | Getty Images The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. The FDA’s decision means Madrigal Pharmaceuticals […]
Read More
WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected. […]
Read More